Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HotSpot IRF5 inhibitor
- Development stage
- Preclinical
- Lead developer
- HotSpot Therapeutics
- Modality
- Small Molecules
- Administration
- Oral, Intraperitoneal
01
Overview
HotSpot Therapeutics is developing a first-in-class small molecule inhibitor of Interferon Regulatory Factor 5 (IRF5) for the treatment of autoimmune diseases, including systemic lupus erythematosus (SLE), Sjögren's syndrome, rheumatoid arthritis (RA), systemic sclerosis (SSc), and myositis. IRF5 is a transcription factor that acts as a master regulator of innate immunity; its dysregulation is linked to the production of pro-inflammatory cytokines and type I interferons. Discovered via the proprietary Smart Allostery™ platform, the inhibitor targets a "natural hotspot"—a previously unknown allosteric pocket critical for the protein's endogenous regulation. Preclinical data demonstrate that the compound provides dose-dependent inhibition of IRF5 phosphorylation and nuclear translocation. In December 2022, AbbVie entered into an exclusive worldwide collaboration and option to license agreement for the program.
- Other names
- IRF5 inhibitorIRF-5 inhibitorIRF 5 inhibitor
02
Targets
IRF5 (Interferon regulatory factor 5)
Beyond the preview
Go deeper on HotSpot IRF5 inhibitor.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HotSpot IRF5 inhibitor.